Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

- PMLiVE

Germany’s Vivoryon raises €43m for Alzheimer’s drug trial

Results of European study expected in 2022

- PMLiVE

New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare

The latest movers in healthcare comms

- PMLiVE

GSK gets FDA okay for wider use of PARP drug Zejula

New approval should help it gain some ground from AZ's rival Lynparza

AstraZeneca AZ

AZ reports growth again in Q3, driven by oncology and China sales

Company has also returned to growth in Europe

- PMLiVE

UPDATED: Ohio opioid trial averted by last-minute settlement

Drug manufacturers reach settlement hours before trial set to begin

- PMLiVE

New hires at Amgen, Eli Lilly and Zosano

The latest movers in pharma

- PMLiVE

Creating value from value-based healthcare

Why pharma companies need to implement novel business models and more

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combo scores in front-line lung cancer

Makes case for duo therapy in NSCLC patients

- PMLiVE

Janssen files Tremfya for psoriatic arthritis in Europe

Hopes to extend use beyond plaque psoriasis

- PMLiVE

UK rations AZ’s paediatric flu vaccine after delivery delays

Supplies may be limited as flu season begins

- PMLiVE

Biogen and Eisai revive abandoned aducanumab in shock turnaround

Companies plan to file the deserted Alzheimer’s drug with FDA

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links